This study recommends the use of EUROIMMUN Anti-SARS-CoV-2 IgA and IgG 1) as a complementary diagnostic tests after 14 days when PCR testing is most likely to become unreliable in individuals admitted with symptoms resembling SARS-CoV-2 disease, 2) in a specific subset of patients who are admitted with confirmed disease but who require antibody testing to confirm the presence of SARS-Co-2 multisystem inflammatory disorder or in patients admitted to intensive care for prognostication and 3) for seroprevalence surveys. The gene discussed is CD79A; the disease is severe acute respiratory syndrome.